Conference Presentation
April 28 2006 - 11:38AM
RNS Non-Regulatory
Aortech International PLC
28 April 2006
For Immediate Release 28 April 2006
AorTech International plc
("AorTech" or the "Company")
AorTech International (AIM.AOR), is pleased to announce that Dr. Carlos Ruiz,
MD, PhD of the Lennox Hill Heart and Vascular Institute of New York made a
presentation today at the opening of the Transcatheter Valve Symposium (TVS-3),
in California, USA, regarding the performance and advantages of the AorTech
M-95-C polymer tri-leaflet heart valve.
Dr Ruiz is a Director of the Trans-Cather Valve Symposium and a member of its
Board. He has no financial interest in or any commercial collaboration with
AorTech.
AorTech's polymer heart valve, the M-95-C was developed by AorTech International
and is manufactured using its proprietary biostable material Elast-Eon(TM).
AorTech received notification on March 26, 2006 that its patent for this heart
valve, # GB2407146 had been granted in the UK. Patents in other regions are
pending.
Frank Maguire, AorTech CEO, commented:
"We are delighted to have attracted the interest and support of someone of Dr.
Ruiz's stature to make this presentation to his colleagues at this high-profile
meeting. We believe that the M-95-C valve will ultimately be adopted and play a
significant role as a next-generation surgical valve because it combines the
best features of both tissue and mechanical valves and as a percutaneous valve
because of its ability to be compressed into a very small size for catheter
delivery to the heart."
Additional information about the Transcatheter Valve Symposium and AorTech can
be found at www.tvsymposium.com and www.aortech.com
For further information please contact:
AorTech International plc
Frank Maguire, Chief Executive Tel: + 1 801 201 4336
Buchanan Communications Tel: + 44 20 7466 5000
Rebecca Skye Dietrich / Ben Willey
About AorTech
AorTech International plc, is an AIM (Alternative Investment Market), London
listed company which wholly owns AorTech Biomaterials based in Melbourne,
Australia.
AorTech Biomaterials was formed in July 1997 to commercialise a range of medical
grade polyurethanes for medical implants developed by the Commonwealth
Scientific and Industrial Research Organisation (CSIRO).
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAIPMATMMJTBIF